Bio Pharma Dive
MARCH 12, 2021
Elimination of the so-called penny rule in Medicaid could force drugmakers to pay larger rebates on a number of top medicines, including some HIV, diabetes and anti-inflammatory drugs.
World of DTC Marketing
MARCH 8, 2021
SUMMARY: The media loves to blame pharma companies for high healthcare costs, but unless we start to invest in healthy lifestyles, we’re headed for a healthcare crisis the likes of which we have never experienced. The media have targeted pharmaceutical companies for a long time because sensational headlines lead to clicks. Forget the fact that prescription drugs only account for $.10 of every healthcare dollar spent and that hospital chains are raking in cash with PBM’s and insurers
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
MARCH 8, 2021
Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very normal (thirty percent of total cases of NSCLS) in people. [1] It became continually challenging in targeting KRAS transformation bearing tumors in view of the unclear con
Camargo
MARCH 9, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. FDA: Sponsors Seldom Disclose RTF Letters’ Existence or Contents and Often Ignore Agency Advice. The FDA revealed that pharma companies are not forthcoming when they publicly disclose the reasons behind a refuse-to-file (RTF) letter from the Agency.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
MARCH 8, 2021
Results from previous trials have raised questions about the vaccine and how well it works. Data from a large U.S. study could help clear up the confusion.
World of DTC Marketing
MARCH 9, 2021
SUMMARY : DTC marketers are spending tens of millions of dollars on programmatic ads that are full of fraud and have low click-through rates but they have yet to embrace email marketing which has an average click-through rate of 3.43%. There is no doubt that more people are using the Internet for online health searches, but the downside is that there is a lot of bad/false health information online. eMail represents an opportunity for pharmaceutical companies to get closer to their customers w
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioPharma Reporter
MARCH 8, 2021
Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.
Bio Pharma Dive
MARCH 10, 2021
While Vertex is confident in the therapy, which came via the $1 billion acquisition of Semma Therapeutics, it will still be a few years before the company has a good read on its effects in Type 1 diabetes patients.
World of DTC Marketing
MARCH 10, 2021
SUMMARY: In its simplest form, a creative management platform , or CMP, is a cloud-based software that allows marketing teams to create, distribute, and measure the performance of digital advertising. The advantage is that marketing teams can create online ads without relying on an agency but it requires a digital marketer who fully understands the brand’s target customer.
Pharma Times
MARCH 12, 2021
Conditional marketing authorisation closely follows positive opinion from CHMP
pharmaphorum
MARCH 10, 2021
There is no clear evidence that the UK’s £37 billion NHS Test and Trace programme (NHST&T) has an impact on the pandemic, according to a withering report from an influential committee of MPs. In its report the Public Accounts Committee (PAC) noted that Department of Health and Social Care justified the scale of the investment in part on the basis that an effective test and trace system would help avoid a second national lockdown.
Bio Pharma Dive
MARCH 11, 2021
An unconventional strategy is behind the rise of Rocket, a New Jersey biotech whose executives boldly talk of turning into the "Genentech of gene therapy.
World of DTC Marketing
MARCH 11, 2021
SUMMARY: Once again, the “hype” may be bigger than the reality around telehealth. First, people aren’t always completely honest with their doctors. A recent study published in the journal JAMA Network Open found that 60 to 80 percent of patients have been less than fully forthright with their doctors at some point which can be worse with telehealth.
Camargo
MARCH 10, 2021
Technology transfer is a critical step in any drug development program, occurring for various reasons and at different development stages. A sponsor may be looking for a contract development and manufacturing organization (CDMO) for clinical trial manufacturing; to transfer a manufacturing process to a larger, commercial-scale CDMO; or to replace a CDMO that has quality issues.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
MARCH 9, 2021
A machine learning model that screened 1,482 compounds potentially effective for treating coronavirus disease 2019 (COVID-19) has ranked Innovation Pharma’s COVID-19 candidate brilacidin in the top 3% of compounds predicted to be most effective against the novel coronavirus.
Bio Pharma Dive
MARCH 11, 2021
At a public hearing in April, the agency will ask a panel of experts whether three immunotherapies should remain on the market for certain cancer types, the latest step in an industrywide review.
pharmaphorum
MARCH 12, 2021
COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement. Speakers at the NIHR’s recent virtual event for the pharma industry discussed best practices for bringing patient insights into research. The pandemic has forced the industry to embrace virtual patient engagement to an extent that would have seemed unachievable little more than a year ago, but there is much more the industry needs to do to
Pharma Times
MARCH 8, 2021
Data from two Phase III studies demonstrated durable viral suppression in HIV-1 patients
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Mirror
MARCH 12, 2021
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVI
Bio Pharma Dive
MARCH 8, 2021
Initial results from a mid-stage study indicate the antiviral drug, molnupiravir, is safe. But whether it's hitting the study's main goal remains unclear.
pharmaphorum
MARCH 11, 2021
European safety regulators have launched an investigation into the safety of a batch of the Oxford University/AstraZeneca COVID-19 vaccine, as countries including Denmark suspended its use as a precaution following reports of blood clots. Initial findings showed no issue with the shots suspended by Austrian authorities after a person was diagnosed with severe blood clotting and died 10 days after vaccination.
Pharma Times
MARCH 10, 2021
Agreement aims to safeguard rights of people receiving health and social care in England
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Mirror
MARCH 10, 2021
A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive covid legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five years, mRNA platforms to transform many new non-infectious disease treatment options, and
Bio Pharma Dive
MARCH 8, 2021
Four years after negative study results, the pharma withdrew the indication as the FDA's "industry-wide evaluation" of accelerated approvals progresses.
pharmaphorum
MARCH 9, 2021
Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. COVID has seen pharma sales experience three years’ worth of digital transformation in the space of just a few months – but while the industry has embraced digital tools and techniques, most companies are still far from
VirTrial
MARCH 8, 2021
Scottsdale, AZ – (March 9, 2021) – VirTrial , the leading provider of telemedicine technology, and uMotif , the patient-centric data capture platform provider, are joining forces to combine their Decentralized Clinical Trial (DCT) technologies in one seamlessly integrated solution. VirTrial’s telemedicine platform provides robust and compliant video consultation capabilities to effortlessly connect site and patient.
Pharma Mirror
MARCH 9, 2021
Davis, CA: Botanical Solution Inc. (BSI) and Syngenta, two companies which are closely aligned in their commitment to innovation and sustainability in agriculture, announce that they have reached an agreement to commercialize BSI’s first product in Peru and Mexico. The two companies have already commercialized successfully the product in Chile under the trade name BotristopÒ.
Bio Pharma Dive
MARCH 9, 2021
An agreement to acquire Maverick Therapeutics for up to $525 million has roots in a plan hatched by Takeda to emulate elements of Celgene's dealmaking strategy.
pharmaphorum
MARCH 12, 2021
Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep quality. . The SleepHub device – developed by Barkby group company Cambridge Sleep Sciences – is on the face of it a box and speakers that plays relaxing noises to help you fall asleep more easily, but is underpinned by a sound wave technology that its developer claims prompt the brain into the activity pattern
BioSpace
MARCH 8, 2021
A drug to halt the progression of Alzheimer’s disease will likely be approved within the next three years, and Alzheon’s ALZ-801 might be the leading candidate.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
336 
Let's personalize your content